Abstract
Histone deacetylases (HDACs) play a key role in the homeostasis of histone acetylation and gene transcription. Histone hypoacetylation and transcriptional dysfunction have been identified in a large number of neurological diseases, including ischemic and hemorrhagic stroke. HDAC inhibitors (HDACi) have emerged as a promising therapeutic intervention in neurodegenerative disorders. Here we review and discuss recent observations in the application of the HDACi to combat the effects of stroke in animal and cell culture models. These agents raise histone acetylation levels, adjust the transcription of associated genes, and exert neuroprotective benefits against stroke. Clinical randomized trials should be performed to further investigate the benefits of HDACi for stroke patients.
Keywords: Histone deacetylase inhibitors, stroke, histone, histone deacetylase (HDAC), histone acetyltransferase (HAT), valproic acid (VPA), sodium butyrate (SB), sodium phenylbutyrate (NaPB), trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), neuroprotection, chromatin, intracerebral hemorrhage (ICH), cerebral ischemia (CI), apoptosis, neuroinflammation, excitotoxicity, oxidative stress, neurotrophin, neurogenesis, histone acetylation, clinical randomed trial (RCT), central nervous system (CNS), brain edema, epidemiology
Central Nervous System Agents in Medicinal Chemistry
Title: Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Volume: 11 Issue: 2
Author(s): Lei Lv, Yu-Ping Tang, Xiang Han, Xin Wang and Qiang Dong
Affiliation:
Keywords: Histone deacetylase inhibitors, stroke, histone, histone deacetylase (HDAC), histone acetyltransferase (HAT), valproic acid (VPA), sodium butyrate (SB), sodium phenylbutyrate (NaPB), trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), neuroprotection, chromatin, intracerebral hemorrhage (ICH), cerebral ischemia (CI), apoptosis, neuroinflammation, excitotoxicity, oxidative stress, neurotrophin, neurogenesis, histone acetylation, clinical randomed trial (RCT), central nervous system (CNS), brain edema, epidemiology
Abstract: Histone deacetylases (HDACs) play a key role in the homeostasis of histone acetylation and gene transcription. Histone hypoacetylation and transcriptional dysfunction have been identified in a large number of neurological diseases, including ischemic and hemorrhagic stroke. HDAC inhibitors (HDACi) have emerged as a promising therapeutic intervention in neurodegenerative disorders. Here we review and discuss recent observations in the application of the HDACi to combat the effects of stroke in animal and cell culture models. These agents raise histone acetylation levels, adjust the transcription of associated genes, and exert neuroprotective benefits against stroke. Clinical randomized trials should be performed to further investigate the benefits of HDACi for stroke patients.
Export Options
About this article
Cite this article as:
Lv Lei, Tang Yu-Ping, Han Xiang, Wang Xin and Dong Qiang, Therapeutic Application of Histone Deacetylase Inhibitors for Stroke, Central Nervous System Agents in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/187152411796011330
DOI https://dx.doi.org/10.2174/187152411796011330 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Inflammatory, Metabolic, and Cell Survival Pathways Contributing to Cerebral Small Vessel Disease by Postmortem Gene Expression Microarray
Current Neurovascular Research Triptolide Rescues Spatial Memory Deficits and Amyloid-β Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice
Current Alzheimer Research Neural Differentiation and Therapeutic Potential of Adipose Tissue Derived Stem Cells
Current Stem Cell Research & Therapy Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Current Medicinal Chemistry Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets An Update on GABA Analogs for CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) Ocular Biomarkers of Alzheimer’s Disease
Central Nervous System Agents in Medicinal Chemistry Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Pharmacological Approaches to Chronic Spinal Cord Injury
Current Pharmaceutical Design Systemic Oxidative Stress in Older Patients with Mild Cognitive Impairment or Late Onset Alzheimer's Disease
Current Alzheimer Research New Approaches for the Selection and Evaluation of Anti-Prion Organic Compounds
Mini-Reviews in Medicinal Chemistry Review on the Protective Effects of PACAP in Models of Neurodegenerative Diseases In Vitro and In Vivo
Current Pharmaceutical Design Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics
Current Pharmaceutical Design Efficacy of Vitamins B Supplementation on Mild Cognitive Impairment and Alzheimer`s Disease: A Systematic Review and Meta-Analysis
Current Alzheimer Research C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Meet Our Associate Editorial Board Member
Current Psychopharmacology Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology